IB1001 not checked

IntraBio Inc

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
5 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa; Study Part 2: Non-randomized, open-label evaluation of prophylaxis and on demand IB1001; Surgical Sub-study: Open-label evaluation of IB1001 during major surgery”In the company’s words, NCT00768287 on ClinicalTrials.gov
Tested for
Hemophilia B (2 trials), Niemann-Pick Disease, Type C, GM2 Gangliosidosis, Tay-Sachs Disease, Sandhoff Disease, Ataxia Telangiectasia
Main trialPhase 3
“The Study's Primary Objective is to evaluate the pharmacokinetics, safety (acute effects associated with infusions, and inhibitor development) and efficacy (breakthrough bleeding and control of hemorrhaging during prophylaxis) of IB1001 in previously treated pediatric subjects with hemophilia B.”In the company’s words, NCT01271868 on ClinicalTrials.gov
Other names
N-Acetyl-L-Leucine · IXINITY · Recombinant factor IX

Other drugs for Hemophilia B

All 7 drugs for Hemophilia B

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Terminated Dec 2016 Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B
Phase 2/3Completed Mar 2013 Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B
Phase 2Completed 7 Nov 2022 N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
Phase 2Completed 9 Jan 2023 N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)
Phase 2Terminated 11 Feb 2025 N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow IB1001

Following is part of Solo: you see every change to IB1001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in